Journal of Allergy / 2014 / Article / Tab 11

Clinical Study

Treatment of Allergic Rhinitis with Ectoine Containing Nasal Spray and Eye Drops in Comparison with Azelastine Containing Nasal Spray and Eye Drops or with Cromoglycic Acid Containing Nasal Spray

Table 11

Comparison of the current study 1 with other azelastine studies.

StudyTreatment % improvement from
baseline to end of
treatment
TNSSTOSS

Current study 11Ectoine 58.8545.96
Azelastine 57.1144.98

Current study 12Ectoine 24.6819.57
Azelastine 35.2611.81

Lumry et al. 2007 (study 1)3 [18]Azelastine 14.1n.d.
Placebo 4.5n.d.

Lumry et al. 2007 (study 2)3 [18]Azelastine 22.1n.d.
Placebo 12.0n.d.

Shah et al.4 [19]Azelastine 0.1%24.4n.d.
Azelastine 0.15%29.7n.d.
Placebo 12.0n.d.

Howland et al.5 [20]Azelastine 0.15%19.316.7
Placebo 11.46.0

Van Bavel et al.6 [21]Azelastine 0.15%18.7n.d.
Placebo 10.5n.d.

Falser et al.7 [22]Azelastine 83.56*n.d.
Levocabastine70.42*n.d.

Charpin et al.8 [23]Azelastine 60.265.0
Cetirizine (tablet)63.360.8

Physicians assessment; 2patients’ assessment; 3one spray of 0.1% azelastine nasal spray per nostril twice daily for 14 days; 4two sprays of 0.1% or 0.15% azelastine nasal spray per nostril twice daily for 14 days; 5two sprays of 0.15% azelastine nasal spray per nostril once daily for 14 days; 6two sprays of 0.15% azelastine nasal spray per nostril once daily for 2 weeks; 7azelastine 1.12 mg/day and levocabastine 0.4 mg/day nasal spray administered twice daily for 4 weeks, TNSS: sneezing, nasal itching, and rhinorrhoea; 8one spray of 0.1% azelastine nasal spray per nostril twice daily for 14 days. n.d.: not determined.